Krystal Biotech Inkomsten in het verleden
Verleden criteriumcontroles 4/6
Krystal Biotech heeft de winst zien groeien met een gemiddeld jaarlijks percentage van 66%, terwijl de Biotechs-industrie de winst zag groeien met 33.7% per jaar. De inkomsten zijn gegroeid met een gemiddeld jaarlijks percentage van 69%. Het rendement op eigen vermogen van Krystal Biotech is 17.8%, en het heeft een nettomarge van 54.8%.
Belangrijke informatie
65.97%
Groei van de winst
65.85%
Groei van de winst per aandeel
| Biotechs Groei van de industrie | 17.04% |
| Inkomstengroei | 68.96% |
| Rendement op eigen vermogen | 17.77% |
| Nettomarge | 54.82% |
| Laatste winstupdate | 30 Jun 2026 |
Recente prestatie-updates uit het verleden
Recent updates
Narratiefupdate • Sep 03
KRYS: Future Ophthalmology And CF Readouts Will Drive Long Term Upside
Analysts have raised their central price target for Krystal Biotech stock from $371 to $474 as they factor in higher projected revenue growth, a higher future P/E multiple, and broader potential for the company's HSV-1 based gene therapy platform in dermatology, ocular, and lung indications. Analyst Commentary on Krystal Biotech Recent Street research on Krystal Biotech points to a cluster of higher price targets and supportive commentary around both the commercial rollout of Vyjuvek and the breadth of the HSV-1 gene therapy platform.
Narratiefupdate • Aug 19
KRYS: Future Returns Will Hinge On 2026 Ophthalmology And CF Readouts
Analysts lifted their blended fair value estimate for Krystal Biotech stock from about $362 to $385, citing higher assumed revenue growth, improved profit margin assumptions, and a lower future P/E multiple, supported by recent price target updates that emphasize the potential of Vyjuvek and the broader pipeline in eye and lung indications. Analyst Commentary Recent Street commentary on Krystal Biotech highlights a mix of optimism around Vyjuvek and the broader pipeline, alongside some caution on execution and upcoming data.
Narratiefupdate • Aug 05
KRYS: Ophthalmology Readouts Will Test Overextended Pipeline Expectations
Analysts have increased their consolidated fair value estimate for Krystal Biotech stock from $241 to $284, reflecting updated price targets that weigh mixed Q2 feedback against ongoing expectations for product demand, pipeline progress, and new asset contributions. Analyst Commentary Recent Street research on Krystal Biotech shows a wide range of fair value views, with several firms setting targets in the high US$300s to mid US$400s and maintaining positive ratings even after what some describe as a mixed Q2 report.Seeking Alpha • Jul 29
Krystal Biotech: Profitable, Self-Funding, And Loaded With Optionality
Summary Krystal Biotech remains a Buy as VYJUVEK drives profitability and its HSV-1 platform underpins a robust pipeline. Q1 results highlight operating leverage: $116.4M VYJUVEK revenue, $56M net income, and self-funded R&D with a $1B cash position. Upcoming catalysts include registrational data for KB803 and KB801, with KB801 positioned as a potential blockbuster in rare ophthalmology. KRYS trades at a premium valuation, justified by pipeline optionality and near-term catalysts, though risks include clinical failures and reliance on VYJUVEK. Read the full article on Seeking AlphaNarratiefupdate • Jul 22
KRYS: Future Returns Will Weigh UK Approval Against 2026 Ophthalmology And CF Data
Krystal Biotech's analyst price target has been reset higher from $349.78 to $361.67. Analysts point to updated assumptions that include slightly lower discount rates, modestly adjusted growth and margin inputs, and increased confidence in future product contributions reflected in higher outer year revenue expectations and P/E multiples.Narratiefupdate • Jul 07
KRYS: Future Returns Will Balance UK Approval With 2026 Pipeline Execution Risks
Krystal Biotech's implied analyst price target in this framework has shifted higher by about $27 to $349.78, as analysts factor in expected value from late stage dermatology data, early cystic fibrosis readouts and the first inclusion of the inhaled KB707 program. Analyst Commentary Recent Street research on Krystal Biotech points to a wide range of views on how the current pipeline and data catalysts may translate into long term value.Narratiefupdate • Jun 23
KRYS: Ophthalmology Readouts And KB707 Lung Data Will Test Pipeline Expectations
The analyst price target for Krystal Biotech has shifted, with updated models incorporating revised discount rate and growth assumptions, along with expectations for pipeline catalysts that include TD Cowen's move to $403, H.C. Wainwright's to $361, and fresh contributions from new asset KB707 and other late stage ophthalmology programs. Analyst Commentary on Krystal Biotech Recent research on Krystal Biotech highlights a mix of optimism around its pipeline and caution around execution, timelines, and how much future opportunity is already reflected in the stock.Narratiefupdate • Jun 09
KRYS: Future Returns Will Reflect UK Approval And Mixed Execution Debate
Krystal Biotech's analyst price target has shifted modestly by a few dollars as analysts factor in recent mixed revisions, including small upward moves from several firms and a larger $27 adjustment from another, while keeping core valuation inputs such as fair value, discount rate, revenue growth, profit margin, and future P/E essentially unchanged. Analyst Commentary Recent research updates around Krystal Biotech reflect both optimism and caution, with several firms adjusting price targets in different directions while keeping core assumptions broadly intact.Narratiefupdate • May 26
KRYS: Future Returns Will Reflect UK Approval And Debated Execution Risks
Krystal Biotech's updated fair value estimate has shifted from $315 to about $322.78 as analysts adjust models around revenue growth, margins, and P/E assumptions. This reflects the mixed but generally supportive reset in Street price targets following recent research updates from multiple firms.Analyse-artikel • May 13
There May Be Underlying Issues With The Quality Of Krystal Biotech's (NASDAQ:KRYS) Earnings
Krystal Biotech, Inc. ( NASDAQ:KRYS ) just reported some strong earnings, and the market reacted accordingly with a...Narratiefupdate • May 01
KRYS: Future Returns Will Reflect Lung Cancer RMAT Milestone And Oncology Pipeline Execution
Analysts have raised their average price target on Krystal Biotech from $291 to $315. This reflects updated models that incorporate Vyjuvek sales assumptions, FY25 financials, and progress across multiple registrational programs following the latest Q4 report and management meetings.Narratiefupdate • Apr 17
KRYS: Oncology Immunotherapy RMAT And Respiratory Programs Will Test Rare Disease Optimism
Analysts have lifted their average price target on Krystal Biotech by $7, reflecting updates to models around Vyjuvek sales expectations, FY25 financials, and the advancing pipeline, while incorporating a slightly higher discount rate and modestly revised revenue growth, profit margin, and P/E assumptions. Analyst Commentary Recent Street research on Krystal Biotech shows a wide spread of opinion, with several firms lifting price targets following the latest quarterly report and updated models for Vyjuvek and the broader pipeline.Narratiefupdate • Apr 01
KRYS: Future CF And Ophthalmology Readouts Will Drive Long Term Upside
Krystal Biotech's analyst price target is maintained at $371, with analysts pointing to refined revenue growth and margin assumptions, along with Q4-driven updates to Vyjuvek forecasts and the broader pipeline, as key supports for the current valuation framework. Analyst Commentary Bullish analysts have been steadily revisiting their models on Krystal Biotech following recent updates on Vyjuvek, the broader pipeline, and Q4 results.Narratiefupdate • Mar 18
KRYS: Future CF And Ophthalmology Readouts Will Shape Long Term Upside
Narrative Update on Krystal Biotech The analyst fair value estimate for Krystal Biotech has shifted from $336 to $371, with the change largely tied to higher Vyjuvek sales assumptions, updated FY25 forecasts, and continued progress across multiple registrational and pivotal pipeline programs cited in recent research updates. Analyst Commentary Recent research updates on Krystal Biotech point to a cluster of upward price target revisions, with bullish analysts citing refreshed financial models, Vyjuvek launch assumptions, and advancing clinical programs across multiple indications as key inputs.Narratiefupdate • Mar 04
KRYS: Rising Oncology And Respiratory Pipeline Expectations May Test Rare Disease Optimism
The analyst price target for Krystal Biotech has been raised from $202 to $241, with analysts pointing to updated models that reflect higher Vyjuvek sales assumptions, refined FY25 financials, and advancing registrational trials across multiple programs. Analyst Commentary Recent Street research on Krystal Biotech highlights a series of upward price target revisions clustered around the latest quarterly update, Vyjuvek launch assumptions, and progress across the pipeline.Narratiefupdate • Feb 18
KRYS: Future Returns Will Reflect Vyjuvek Penetration And CF And Oncology Pipeline Execution
Narrative Update: Krystal Biotech Analyst Price Target Shift The analyst price target for Krystal Biotech has been revised higher from $273.60 to $291.22, with analysts pointing to recent model updates that reflect Vyjuvek demand trends, advancing ophthalmology programs, and early data from the broader pipeline. Analyst Commentary Recent Street research on Krystal Biotech points to a cluster of upward price target revisions, with most commentary tying those changes to product traction for Vyjuvek, the maturing ophthalmology pipeline, and early data in cystic fibrosis and other programs.Narratiefupdate • Feb 04
KRYS: Future CF Data Readouts May Redefine Long Term Upside Potential
Analysts have increased their price target on Krystal Biotech from $252 to $336, citing updated models that factor in revised assumptions for revenue growth, profit margins, and future P/E multiples following recent clinical data and pipeline updates. Analyst Commentary Recent Street research on Krystal Biotech has centered on a series of higher price targets, with bullish analysts revisiting their models after clinical updates and product pipeline progress.Narratiefupdate • Jan 21
KRYS: Future Returns Will Reflect 96% Margins And Early CF Pipeline Progress
We are raising our analyst price target on Krystal Biotech from $223 to $273.60. This reflects updated models that incorporate recent analyst work on Vyjuvek, early KB407 cystic fibrosis data, and revised assumptions for revenue growth, profit margin, and future P/E multiples.Narratiefupdate • Jan 07
KRYS: Elevated Expectations For Rare Disease Portfolio May Prove Unsustainable
Analysts have lifted their Krystal Biotech fair value estimate from US$176 to US$202, citing higher price targets from recent research, improving access to capital for biotech, and support from Vyjuvek revenue trends and gross margin performance. Analyst Commentary Recent Street research has generally framed Krystal Biotech within a more constructive backdrop for U.S. biotech, pointing to supportive data readouts, active dealmaking by larger peers, and what some describe as better access to capital.Narratiefupdate • Dec 15
KRYS: Future Returns Will Reflect 96% Margins And Expanding International Uptake
Analysts have nudged their price target on Krystal Biotech higher to about $220, reflecting stronger than expected Vyjuvek revenue, early traction from the Germany launch, and exceptionally high gross margins that support the company’s long term profitability outlook. Analyst Commentary Bullish analysts point to the latest quarter as evidence that Krystal Biotech is executing ahead of expectations, with Vyjuvek demand and geographic expansion translating into faster top line growth and stronger earnings power than previously modeled.Narratiefupdate • Dec 01
KRYS: Future Results Will Reflect Margin Strength and International Launch Performance
Analysts have raised their price target for Krystal Biotech to $220, up from $216. They cite stronger-than-expected Vyjuvek revenue, international sales growth, and robust gross margins as key drivers behind the increased valuation.Narratiefupdate • Nov 17
KRYS: Future Momentum Will Depend on Gross Margin Strength and Pipeline Progress
Analysts have increased Krystal Biotech’s price target from $212.50 to $223.00. They cite stronger-than-expected Vyjuvek revenue, expansion in Germany, and improved profit margins as key factors supporting the higher valuation.Analyse-artikel • Nov 10
Investors Shouldn't Be Too Comfortable With Krystal Biotech's (NASDAQ:KRYS) Earnings
Krystal Biotech, Inc.'s ( NASDAQ:KRYS ) robust earnings report didn't manage to move the market for its stock. Our...Narratiefupdate • Nov 01
KRYS: Global Expansion And Pipeline Shifts Will Shape Near-Term Performance
Krystal Biotech's average analyst price target has been revised downward, with a reduction of up to $10 per share. Analysts cite updated product prioritizations, mixed quarterly results, and cautious near-term revenue forecasts.Narratiefupdate • Oct 18
Global Expansion And Clinical Readouts Will Unlock New Markets
The analyst consensus price target for Krystal Biotech has increased from $205.20 to $212.50. This change reflects updated evaluations as analysts factor in new product development priorities and ongoing commercial performance.Analyse-artikel • Oct 09
Market Participants Recognise Krystal Biotech, Inc.'s (NASDAQ:KRYS) Earnings Pushing Shares 29% Higher
The Krystal Biotech, Inc. ( NASDAQ:KRYS ) share price has done very well over the last month, posting an excellent gain...Seeking Alpha • Feb 21
Krystal Biotech Soars As Q4 Earnings Put Blockbuster Commercialization In Focus
Summary Krystal Biotech's VYJUVEK shows strong growth, with 2025 sales expected to exceed $1B, bolstered by launches in the EU and Japan. Q4 earnings beat EPS expectations but slightly missed revenue forecasts; however, management's 2025 outlook coming catalysts drove a strong rally in shares. Key 2025 catalysts include VYJUVEK's EU and Japan launches, Phase 3 ocular DEB results, and progress in CF and lung gene therapy. KRYS stock remains a STRONG BUY with a $225/share 12-month target, driven by impressive growth and new market opportunities. Read the full article on Seeking AlphaSeeking Alpha • Oct 14
Krystal Biotech: Q4 Catalysts Expected With VYJUVEK Revenue Growth Pressing On
Summary The company anticipates significant Q4 2024 data releases for KB707 in solid tumors and KB408 in AATD lung disease, potentially boosting shareholder value. Jeune Therapeutics, a subsidiary, shows promise in aesthetics with positive phase 1 data, changing the treatment paradigm in the aesthetics market space. VYJUVEK, approved for DEB, saw a 55.3% revenue increase in Q2 2024, with potential European expansion pending MAA approval. Financially stable with $628.9M cash, but may need additional funding within 12 months; has a $150M ATM agreement with Cowen & Co. LLC. in place if necessary. Read the full article on Seeking Alpha
Nieuw narratief • Aug 29
Expanding Global Reach With VYJUVEK Set To Skyrocket Revenue And Sharpen Market Edge
International expansion and upcoming product launches indicate significant potential for revenue growth and market diversification.Seeking Alpha • Jul 31
Krystal Biotech: High Valuation Merits Caution Ahead Of Q2 Earnings (Rating Downgrade)
Summary Krystal Biotech's Q1 2024 revenue increased to $45.25 million but fell short of analyst expectations of $47.37 million. Analysts expect Q2 earnings to be $65.49 million. Vyjuvek's patient adherence rate dropped slightly to 91% in Q1 from 96% in the previous quarter. Krystal's pipeline, beyond dermatological and aesthetic pursuits, is pretty speculative and pursuing highly contested indications. I recommend a rating downgrade "hold" for Krystal due to its high valuation. Read the full article on Seeking AlphaOpbrengsten en kosten
Opbrengsten en kosten
Hoe Krystal Biotech geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 26 | 440 | 241 | 160 | 59 |
| 31 Mar 26 | 417 | 225 | 155 | 59 |
| 31 Dec 25 | 389 | 205 | 147 | 58 |
| 30 Sep 25 | 373 | 199 | 137 | 57 |
| 30 Jun 25 | 359 | 147 | 128 | 56 |
| 31 Mar 25 | 333 | 124 | 120 | 57 |
| 31 Dec 24 | 291 | 89 | 114 | 54 |
| 30 Sep 24 | 242 | 52 | 107 | 51 |
| 30 Jun 24 | 166 | 106 | 102 | 49 |
| 31 Mar 24 | 96 | 57 | 100 | 45 |
| 31 Dec 23 | 51 | 11 | 98 | 46 |
| 30 Sep 23 | 9 | -30 | 98 | 46 |
| 30 Jun 23 | 0 | -140 | 94 | 47 |
| 31 Mar 23 | 0 | -135 | 86 | 45 |
| 31 Dec 22 | 0 | -140 | 79 | 42 |
| 30 Sep 22 | 0 | -130 | 69 | 41 |
| 30 Jun 22 | 0 | -115 | 59 | 35 |
| 31 Mar 22 | 0 | -104 | 51 | 31 |
| 31 Dec 21 | 0 | -70 | 42 | 28 |
| 30 Sep 21 | 0 | -58 | 32 | 25 |
| 30 Jun 21 | 0 | -52 | 27 | 24 |
| 31 Mar 21 | 0 | -43 | 21 | 21 |
| 31 Dec 20 | 0 | -32 | 15 | 18 |
| 30 Sep 20 | 0 | -27 | 12 | 17 |
| 30 Jun 20 | 0 | -22 | 9 | 15 |
| 31 Mar 20 | 0 | -20 | 7 | 16 |
| 31 Dec 19 | 0 | -19 | 6 | 16 |
| 30 Sep 19 | 0 | -17 | 6 | 14 |
| 30 Jun 19 | 0 | -16 | 6 | 12 |
| 31 Mar 19 | 0 | -13 | 5 | 9 |
| 31 Dec 18 | 0 | -11 | 4 | 8 |
| 30 Sep 18 | 0 | -9 | 3 | 6 |
| 30 Jun 18 | 0 | -11 | 3 | 5 |
| 31 Mar 18 | 0 | -10 | 2 | 4 |
| 31 Dec 17 | 0 | -8 | 2 | 3 |
| 30 Sep 17 | 0 | -7 | 1 | 3 |
| 30 Jun 17 | 0 | -2 | 1 | 1 |
Kwaliteitswinsten: KRYS heeft hoge kwaliteitsinkomsten.
Groeiende winstmarge: De huidige netto winstmarges (54.8%) KRYS } zijn hoger dan vorig jaar (40.8%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: KRYS is de afgelopen 5 jaar winstgevend geworden en heeft de winst met 66% per jaar laten groeien.
Versnelling van de groei: De winstgroei van KRYS over het afgelopen jaar ( 64.6% ) ligt onder het 5-jarig gemiddelde ( 66% per jaar).
Winst versus industrie: De winstgroei KRYS over het afgelopen jaar ( 64.6% ) overtrof de Biotechs -sector 64.6%.
Rendement op eigen vermogen
Hoge ROE: Het Rendement op eigen vermogen ( 17.8% ) van KRYS wordt als laag beschouwd.
Rendement op activa
Rendement op geïnvesteerd vermogen
Ontdek sterk presterende bedrijven uit het verleden
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/09/18 13:55 |
| Aandelenkoers aan het einde van de dag | 2026/09/18 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Krystal Biotech, Inc. wordt gevolgd door 20 analisten. 9 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Caroline Palomeque | Berenberg |
| Alec Stranahan | BofA Global Research |
| Justin Zelin | B. Riley Securities, Inc. |